| pubmed-article:2470898 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2470898 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:2470898 | lifeskim:mentions | umls-concept:C0001643 | lld:lifeskim |
| pubmed-article:2470898 | lifeskim:mentions | umls-concept:C0024264 | lld:lifeskim |
| pubmed-article:2470898 | lifeskim:mentions | umls-concept:C0044222 | lld:lifeskim |
| pubmed-article:2470898 | lifeskim:mentions | umls-concept:C1449702 | lld:lifeskim |
| pubmed-article:2470898 | lifeskim:mentions | umls-concept:C0178702 | lld:lifeskim |
| pubmed-article:2470898 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2470898 | lifeskim:mentions | umls-concept:C1514758 | lld:lifeskim |
| pubmed-article:2470898 | lifeskim:mentions | umls-concept:C0205266 | lld:lifeskim |
| pubmed-article:2470898 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:2470898 | pubmed:dateCreated | 1989-6-26 | lld:pubmed |
| pubmed-article:2470898 | pubmed:abstractText | To investigate the role of protein kinases in agonist-mediated beta-2 adrenergic receptor regulation, the effects of the protein kinase A and C inhibitor, H-7 [1-(5-isoquinolinylsulfonyl)-2-methylpiperazine], on isoproterenol-induced beta adrenoceptor activation and desensitization have been studied in intact human lymphocytes. In the presence of the phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthine, H-7 potentiated 10(-8) to 10(-4) M isoproterenol or prostaglandin E1-induced cyclic AMP (cAMP) accumulation in a dose-dependent manner. We failed to observe any effect of H-7 on forskolin-induced cAMP accumulation. These effects of H-7 are probably not due to its inhibition of phosphodiesterase. In addition, whereas up to 10(-3) M H-7 had no beta adrenergic receptor blocking effect, preincubation of intact cells with 10(-3.5) M H-7 partially prevented 50 nM isoproterenol-induced beta-2 adrenergic receptor desensitization in terms of decreases in beta adrenoceptor density (maximum binding), isoproterenol-mediated cAMP responsiveness and high affinity receptor binding for agonist. Interestingly, 10(-3.5) M H-7 alone treated cells also showed an up-regulation of cell surface beta receptor density (maximum binding) and increased cAMP responsiveness to isoproterenol stimulation. The mechanisms are unclear. If these effects occur as a result of inhibition by H-7 of protein kinase A and/or C, it may suggest an important role of protein kinase A and/or C in agonist-induced beta-2 adrenergic receptor regulation. | lld:pubmed |
| pubmed-article:2470898 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2470898 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2470898 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2470898 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2470898 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2470898 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2470898 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2470898 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2470898 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2470898 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2470898 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2470898 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2470898 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2470898 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2470898 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2470898 | pubmed:month | May | lld:pubmed |
| pubmed-article:2470898 | pubmed:issn | 0022-3565 | lld:pubmed |
| pubmed-article:2470898 | pubmed:author | pubmed-author:HuiK KKK | lld:pubmed |
| pubmed-article:2470898 | pubmed:author | pubmed-author:YuJ LJL | lld:pubmed |
| pubmed-article:2470898 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2470898 | pubmed:volume | 249 | lld:pubmed |
| pubmed-article:2470898 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2470898 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2470898 | pubmed:pagination | 492-8 | lld:pubmed |
| pubmed-article:2470898 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:2470898 | pubmed:meshHeading | pubmed-meshheading:2470898-... | lld:pubmed |
| pubmed-article:2470898 | pubmed:meshHeading | pubmed-meshheading:2470898-... | lld:pubmed |
| pubmed-article:2470898 | pubmed:meshHeading | pubmed-meshheading:2470898-... | lld:pubmed |
| pubmed-article:2470898 | pubmed:meshHeading | pubmed-meshheading:2470898-... | lld:pubmed |
| pubmed-article:2470898 | pubmed:meshHeading | pubmed-meshheading:2470898-... | lld:pubmed |
| pubmed-article:2470898 | pubmed:meshHeading | pubmed-meshheading:2470898-... | lld:pubmed |
| pubmed-article:2470898 | pubmed:meshHeading | pubmed-meshheading:2470898-... | lld:pubmed |
| pubmed-article:2470898 | pubmed:meshHeading | pubmed-meshheading:2470898-... | lld:pubmed |
| pubmed-article:2470898 | pubmed:meshHeading | pubmed-meshheading:2470898-... | lld:pubmed |
| pubmed-article:2470898 | pubmed:meshHeading | pubmed-meshheading:2470898-... | lld:pubmed |
| pubmed-article:2470898 | pubmed:meshHeading | pubmed-meshheading:2470898-... | lld:pubmed |
| pubmed-article:2470898 | pubmed:meshHeading | pubmed-meshheading:2470898-... | lld:pubmed |
| pubmed-article:2470898 | pubmed:meshHeading | pubmed-meshheading:2470898-... | lld:pubmed |
| pubmed-article:2470898 | pubmed:meshHeading | pubmed-meshheading:2470898-... | lld:pubmed |
| pubmed-article:2470898 | pubmed:meshHeading | pubmed-meshheading:2470898-... | lld:pubmed |
| pubmed-article:2470898 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2470898 | pubmed:articleTitle | Effects of protein kinase inhibitor, 1-(5-isoquinolinylsulfonyl)-2-methylpiperazine, on beta-2 adrenergic receptor activation and desensitization in intact human lymphocytes. | lld:pubmed |
| pubmed-article:2470898 | pubmed:affiliation | Department of Medicine, School of Medicine, University of California, Los Angeles. | lld:pubmed |
| pubmed-article:2470898 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2470898 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:154 | entrezgene:pubmed | pubmed-article:2470898 | lld:entrezgene |
